Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients

References

• Appel SH, Almon RR, Levy N. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med 1975; 293:760–761.
   Google Scholar
• Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054–1059.
   Google Scholar
• Hohlfeld R, Toyka KV, Tzartoss SJ, Carson W, Conti-Tronconi B. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor a subunit. Proc Natl Acad Sci USA 1987;84:5379–5383.
   Google Scholar
• Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci 2003;998:457–472.
   PubMedGoogle Scholar
• Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40:786–790.
   Google Scholar
• Bell J, Rassenti L, Smoot S, Smith K, Newby C, Hohlfeld R, Toyka K, McDevitt H, Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet 1986;i:1058–1060.
   Google Scholar
• Christadoss P, Lindstrom JM, Melvold RW, Talal N. Mutation at I-A beta chain prevents experimental auto-immune myasthenia gravis. Immunogenetics 1985;21: 33–38.
   PubMed Web of Science ®Google Scholar
• Oshima M, Atassi MZ. Effect of amino acid substitutions within the region 62-76 of I-A13' on binding with and antigen presentation of Torpedo acetylcholine receptor a chain peptide 146-162. J Immunol 1995;154:5245–5254.
   PubMed Web of Science ®Google Scholar
• Infante AJ, Thompson PA, Krolick KA, Wall KA. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J Immunol 1991;146: 2977–2982.
   Google Scholar
• Bellone M, Ostlie N, Lei S, Wu X-D, Conti-Tronconi BM. The I-Abm12 mutation, which confers resistance to exper-imental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J Immunol 1991;147: 1484–1491.
   Google Scholar
• Shenoy M, Oshima M, Atassi MZ, Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region a146-162 of acetylcholine receptor. Chin Immunol Immunopath 1993;66: 230–238.
   PubMedGoogle Scholar
• Nakayashiki N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J Neuro-immunol 2000;105:131–144.
   Google Scholar
• Oshima M, Deitiker P, Ashizawa T, Atassi MZ. Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity 2002;35:183–190.
   PubMed Web of Science ®Google Scholar
• Garchon HJ. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J Autoimmun 2003;21:105–110.
   PubMedGoogle Scholar
• Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M. HLA antigens in Japanese patients with myasthenia gravis. J Chin Invest 1990;86: 392–399.
   PubMed Web of Science ®Google Scholar
• Hjelmstrom P, Peacock CS, Giscombe R, Pirskanen R, Lefvert AK, Blackwell JM, Sanjeevi CB. Myasthenia gravis with thymic hyperplasia is associated with polymorphisms in the tumor necrosis factor region. Ann N Y Acad Sci 1998;841:368–370.
   Google Scholar
• Horiki T, Inoko H, Moriuchi J, Ichikawa Y, Arimori S. Combinations of HLA-DPB1 and HLA-DQB1 allelesdetermine susceptibility to early-onset myasthenia gravis in Japan. Autoimmunity 1994;19: 49–54.
   Google Scholar
• Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach J-F. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol 1993;47:115–122.
   PubMed Web of Science ®Google Scholar
• Baggi F, Antozzi C, Andreetta F, Confaloniri P, Ciusani E, Begovich AB, Erlich HA, Cornelio A, Mantegazza R. Identification of a novel HLA class II association with DQB1*0502 in an Italian myasthenic population. Ann N Y Acad Sci 1998;841: 355–359.
   Google Scholar
• Hjelmstrom P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, Landin-Olsson M, Sanjeevi CB. Polymorphic amino acid domains of the HLA-DQ molecules are associated with disease heterogeneity in myasthenia gravis. J Neuroim-munol 1996;65:125–131.
   Google Scholar
• Suzuki S, Kuwana M, Yasuoka H, Tanaka K, Fukuuchi Y, Kawakami Y. Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis. J Neurol Sci 2001;189:59–64.
   PubMed Web of Science ®Google Scholar
• Yasunaga S, Kimura A, Hamaguchi K, Ronningen KS, Sasazuki T. Different contribution of HLA-DR and -DQ genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). Tissue Antigens 1996;47:37–48.
   Google Scholar
• Atassi MZ, Kazim AL, Sakata S. High yield coupling of peptides to protein carriers. Biochim Biophys Acta 1981;670:300–302.
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B, Manshouri T, Yokoi T, Atassi MZ. The regions of a-neurotoxin binding on the extracellular part of the a-subunit of human acetylcholine receptor. J Prot Chem 1988;7:173–177.
   Google Scholar
• Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, et al. Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000;55:16–23.
   PubMedGoogle Scholar
• Oshima M, Ashizawa T, Pollack MS, Atassi MZ. Autoimmune T cell recognition of human acetylcholine receptor: The sites of T cell recognition in myasthenia gravis on the extra-cellular part of the « subunit. Eur J Immunol 1990; 20:2563–2569.
   PubMed Web of Science ®Google Scholar
• Giles RC, Nunez G, Hurley CK, Nunez-Roldan A, Winchester R, Stasmy P, Capra JD. Structural analysis of a human I-A homologue using a monoclonal antibody that recognizes an MB3-like specificity. J Exp Med 1983; 157:1461–1470.
   Google Scholar
• Wall M, Southwood S, Sidney J, Oseroff C, del Guericio MF, Lamont AG, Colon SM, Arrhenius T, Gaeta FCA, Sette A. High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants. Int Immunol 1992;4:773–777.
   Google Scholar
• Twining SS, Atassi MZ. Use of immunoadsorbents for the study of antibody binding to sperm whale myoglobin and its synthetic antigenic sites. J Immunol Methods 1979;30: 139–151.
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi B, Toyka Ky. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 1986;36:618–621.
   Google Scholar
• Ofosu-Appiah W, Mokhtarian F, Shirazian D, Grob D. Production of anti-acetylcholine receptor-a antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: Role of immunoregulatory T cells and monocytes. J Lab Chin Med 1994;124: 231–241.
   Google Scholar